Impact of OnabotulinumtoxinA on Quality of Life, Health Resource Utilization, and Work Productivity in People With Chronic Migraine: Interim Results From a Prospective, Observational Study (PREDICT) (P4.10-023)

Objective: To assess long-term health-related quality of life (QoL) in people treated with onabotulinumtoxinA for chronic migraine (CM). Background: CM can impair health-related QoL and daily functioning, resulting in social and economic burden. Design/Methods: Canadian multicentre, prospective, observational study in adults with CM, botulinum toxin naive for migraine (NCT02502123). Based on the Canadian onabotulinumtoxinA product monograph (July 7, 2014), 7 onabotulinumtoxinA treatments were administered post-baseline/screening. This interim analysis includes data from patients who completed 4 treatment sessions (Tx4; ~10 months). Endpoints: Mean change from baseline to Tx4 in Migraine-Specific Quality of Life (MSQ) score (primary); healthcare resource utilization and work productivity (secondary). Results: Patients at baseline (n=196), post-Tx2 (n=173), and post-Tx4 (n=137) received a mean onabotulinumtoxinA dose of 170.4 U (SD=17.2) per session with a mean interval of 13.1 weeks (SD=1.7) between sessions at this interim analysis. OnabotulinumtoxinA treatment significantly (P Conclusions: This interim analysis demonstrated that onabotulinumtoxinA for CM improved health-related QoL and work productivity and reduced healthcare resource utilization. Disclosure: Dr. Boudreau has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Amgen, Lilly, and Teva. Dr. Boudreau has received research support from Allergan, Amgen, Lilly, and Teva. Dr. Becker has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Amgen and Novartis. Dr. Becker has received research support from Allergan and Amgen. Dr. Graboski has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Purdue, Lilly, Tribute, Genzyme, Allergan, and Janssen. Dr. Graboski has received research support from Allergan. Dr. Ong-Lam has received research support from Allergan and Lilly. Dr. Finkelstein has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ian Finkelstein, MD, received grants/honoraria from Allergan, Amgen, Eli Lilly, JJ was a speaker for Allergan, Amgen, Eli Lilly, Teva, and Aralez; and received consulting fees from Allergan, Amgen, Eli Lilly, Tribute, and Novartis. Dr. Christie has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Novartis, Lilly, Amgen, Allergan, and Tribute.. Dr. Christie has received research support from Biogen, Novartis, Lilly, Amgen, Allergan, and Tribute. Dr. Bhogal has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan. Dr. Davidovic has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan plc.